Phytotoxic responses of acrocarpous moss Campylopus schmidii as bioindicators in copper and cadmium contaminated environments: A comprehensive assessment.

Mosses play a vital role in environmental research as reliable biomonitoring tools. This study aims to understand the accumulation and distribution patterns of Cu and Cd in the acrocarpous moss [Campylopus schmidii (Müll. Hal.) A. Jaeger] (C.schmidii). In controlled in vitro experiments, C.schmidii cultures were exposed to varying concentrations of copper (Cu) and cadmium (Cd) stress (0, 10, 25, 50 µmol/L) in aquatic media. The study systematically evaluated the moss's response, including observing appearance features, oxidative traits, and accumulation characteristics. Scanning electron microscopy with energy-dispersive X-ray spectroscopy analyses were employed. They aimed to characterize and determine the distribution of metal particles in different parts of the mosses under high concentration treatments (50 µmol/L Cd, 50 µmol/L Cu, 50 µmol/L Cu and Cd). Results indicated that C.schmidii exhibited greater tolerance to Cu compared to Cd, as evidenced by significantly higher soluble protein content and lipid peroxidation with increasing concentrations. However, Cd stress induced severe damage, including widespread chlorosis, reduced chlorophyll content, and surface fragmentation. Both Cu and Cd were found to stimulate antioxidant levels by increasing the activity of hydrogen peroxide and peroxidase, thus reducing the accumulation of free radicals in C.schmidii. Additionally, the results revealed differential metal distribution. Higher Cu (2.23%) and lower Cd (0.54%) accumulation were observed at the bottom of gametophores, with Cd content 180.46% higher than Cu at the top. This study provides valuable insights into the potential application of acrocarpous mosses for biomonitoring and phytoremediation. It suggests specific strategies for metal deposition and absorption, such as utilizing upper, younger parts for Cd absorption and lower parts for Cu remediation in soil.

Exploring potential SARS-CoV-2 Mpro non-covalent inhibitors through docking, pharmacophore profile matching, molecular dynamic simulation, and MM-GBSA.

CONTEXT: In the replication of SARS-CoV-2, the main protease (Mpro/3CLpro) is significant. It is conserved in a number of novel coronavirus variations, and no known human proteases share its cleavage sites. Therefore, 3CLpro is an ideal target. In the report, we screened five potential inhibitors (1543, 2308, 3717, 5606, and 9000) of SARS-CoV-2 Mpro through a workflow. The calculation of MM-GBSA binding free energy showed that three of the five potential inhibitors (1543, 2308, 5606) had similar inhibitor effects to X77 against Mpro of SARS-CoV-2. In conclusion, the manuscript lays the groundwork for the design of Mpro inhibitors. METHODS: In the virtual screening phase, we used structure-based virtual screening (Qvina2.1) and ligand-based virtual screening (AncPhore). In the molecular dynamic simulation part, we used the Amber14SB + GAFF force field to perform molecular dynamic simulation of the complex for 100 ns (Gromacs2021.5) and performed MM-GBSA binding free energy calculation according to the simulation trajectory.

The genetic variability, phylogeny and functional significance of E6, E7 and LCR in human papillomavirus type 52 isolates in Sichuan, China.

BACKGROUND: Variations in human papillomavirus (HPV) E6 and E7 have been shown to be closely related to the persistence of the virus and the occurrence and development of cervical cancer. Long control region (LCR) of HPV has been shown multiple functions on regulating viral transcription. In recent years, there have been reports on E6/E7/LCR of HPV-16 and HPV-58, but there are few studies on HPV-52, especially for LCR. In this study, we focused on gene polymorphism of the HPV-52 E6/E7/LCR sequences, assessed the effects of variations on the immune recognition of viral E6 and E7 antigens, predicted the effect of LCR variations on transcription factor binding sites and provided more basic date for further study of E6/E7/LCR in Chengdu, China. METHODS: LCR/E6/E7 of the HPV-52 were amplified and sequenced to do polymorphic and phylogenetic analysis. Sequences were aligned with the reference sequence by MEGA 7.0 to identify SNP. A neighbor-joining phylogenetic tree was constructed by MEGA 7.0, followed by the secondary structure prediction of the related proteins using PSIPRED 4.0. The selection pressure of E6 and E7 coding regions were estimated by Bayes empirical Bayes analysis of PAML 4.9. The HLA class-I and II binding peptides were predicted by the Immune Epitope Database server. The B cell epitopes were predicted by ABCpred server. Transcription factor binding sites in LCR were predicted by JASPAR database. RESULTS: 50 SNP sites (6 in E6, 10 in E7, 34 in LCR) were found. From the most variable to the least variable, the nucleotide variations were LCR > E7 > E6. Two deletions were found between the nucleotide sites 7387-7391 (TTATG) and 7698-7700 (CTT) in all samples. A deletion was found between the nucleotide sites 7287-7288 (TG) in 97.56% (40/41) of the samples. The combinations of all the SNP sites and deletions resulted in 12 unique sequences. As shown in the neighbor-joining phylogenetic tree, except for one belonging to sub-lineage C2, others sequences clustered into sub-lineage B2. No positive selection was observed in E6 and E7. 8 non-synonymous amino acid substitutions (including E3Q and K93R in the E6, and T37I, S52D, Y59D, H61Y, D64N and L99R in the E7) were potential affecting multiple putative epitopes for both CD4+ and CD8+ T-cells and B-cells. A7168G was the most variable site (100%) and the binding sites for transcription factor VAX1 in LCR. In addition, the prediction results showed that LCR had the high probability binding sites for transcription factors SOX9, FOS, RAX, HOXA5, VAX1 and SRY. CONCLUSION: This study provides basic data for understanding the relation among E6/E7/LCR mutations, lineages and carcinogenesis. Furthermore, it provides an insight into the intrinsic geographical relatedness and biological differences of the HPV-52 variants, and contributes to further research on the HPV-52 therapeutic vaccine development.